Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 1,366 patients the effect of Nicergoline (Sermion) on symptoms was recorded for one year. Individual symptoms improved to varying degrees in the patients observed. Many influences were responsible for the recorded improvement in the condition of the patients. These included, apart from the selection, placebo effects, the effect of suggestion, increased personal attention due to the need for monitoring examinations, and the pharmacodynamic effects of the active substance. The fact that the improvement rate of several symptoms such as lack of concentration, impairment of memory, decrease in alertness, dizziness and noises in the ear was analogous to that found in placebo-controlled doubleblind studies of other workers permits the assumption, that not so much the effects of placebo and suggestion but above all the pharmacodynamics of the active substance was the important factor. Treatment, which lasted for a year resulted in an improvement in some symptoms even during the second half of the year but not in others. This provides information on the indication for long-term treatment. Analysis of the individual parameters throws light on the reliability of the information provided by the examining physician, the patient compliance and the psychological effects of the physician's activities. Parameterized values are sometimes recorded more reliably by interested auxiliary medical staff than by physicians who feel alienated from their proper duty by such technical tasks.
 ...
PMID:[Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls]. 639 47

In elderly patients, dizziness occurs very frequently with significant effects on the patient's life. Its frequency increases with age, and may arise from a variety of causes. Chronic dysequilibrium in elderly patients is most probably related to disturbances within the central nervous system, due either to altered neuronal functions or to an underlying vascular disease. Nicergoline, a drug used in the treatment of cognitive disturbances in geriatric patients, improves dizziness in elderly demented and non-demented patients. In a double blind,placebo controlled trial the drug improved (i) the severity of symptoms, measured by the dizziness assessment rating scale (DARS), (ii) the overall clinical conditions revealed by global impression scale, and (iii) the perceived quality of life estimated by the dizziness handicap inventory (DHI). These results indicate a possible positive effect also on posturographic measures. Moreover, the improvement occurred at no expense of the established strategy of postural control suggesting that the effect is mediated by a substitute compensatory mechanism allowing the patient to preserve consolidated postural strategies. The results of previous open clinical studies in about 3000 patients are in agreement with those findings. Overall, severity of symptoms decreased by 68 % (57 % in the control study). Globally, the results indicate a beneficial effect of nicergoline on symptoms related to balance disorders of central origin. Animal studies show that the drug displays a broad spectrum of actions on cellular and molecular mechanisms. Moreover, animal research specifically aimed at vestibular pathophysiology has revealed that nicergoline improves vestibular compensation in models of vestibular lesion. Chronic treatment with nicergoline improved the time-course of behavioral recovery in old rats after hemi-labyrinthectomy and counteracted the regulation of cholinergic receptors observed after lesion in old rats. Nicergoline interacts at several levels by various mechanisms, from the molecular level to cognitive function, probably enhancing spontaneous plasticity phenomena underlying the central vestibular compensation. This effect is not dependent from the interaction with a single-transmitter-identified neural pathway, but from anatomical, functional and neurochemical synergistic adjustments in several brain areas.
 ...
PMID:Nicergoline in the treatment of dizziness in elderly patients. A review. 1520 10